Trevena Inc (NAS:TRVN)
$ 6.7 -0.79 (-10.55%) Market Cap: 5.71 Mil Enterprise Value: 26.50 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 23/100

Trevena Inc Business Update Transcript

Sep 06, 2023 / 12:00PM GMT
Release Date Price: $25 (+14.27%)
Operator

Greetings, and welcome to the Trevena corporate update. (Operator Instructions) As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Mr. Barry Shin, Chief Financial Officer for Trevena. Thank you. You may begin.

Barry Shin
Trevena, Inc. - Senior VP & CFO

Great. Thanks, Melissa. Good morning, and thank you for joining us to discuss our proof-of-concept data for TRV045. With me today are Carrie Bourdow, our President and CEO; and our Chief Medical Officer, Mark Demitrack. We'll also touch on other business updates.

And as a reminder, OLINVYK was approved by the FDA in August 2020 and contains oliceridine, an opioid, which is a scheduled to controlled substance with a high potential for abuse similar to other opioids. It's indicated in adults for the management of acute pain severe enough to require an IV opioid analgesic and for whom alternative treatments are inadequate.

As with all opioids, serious life-threatening or fatal respiratory depression may occur in patients treated with

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot